BloomgrenGRichmanSHotermansC. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med2012; 366(20): 1870–1880. doi: 10.1056/NEJMoa1107829.
2.
PlavinaTSubramanyamMBloomgrenG. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol2014; 76(6): 802–812. doi: 10.1002/ana.24286.
3.
OutteryckOZéphirHSalleronJ. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler2014; 20(7): 822–829. doi: 10.1177/1352458513505353.
4.
TrampeAKHemmelmannCStroetA. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology2012; 78(22): 1736–1742. doi: 10.1212/WNL.0b013e3182583022.
5.
WarnkeCRamanujamRPlavinaT. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry2013; 84(11): 1199–1205. doi: 10.1136/jnnp-2012–304332.
6.
BozicCSubramanyamMRichmanS. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol2014; 21(2): 299–304. doi: 10.1111/ene.12304.
7.
OlssonTAchironAAlfredssonL. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler2013; 19(11): 1533–1538. doi: 10.1177/1352458513477925.
8.
HirschHHKardasPKranzD. The human JC polyomavirus (JCPyV): Virological background and clinical implications. Apmis2013; 121(8): 685–727. doi: 10.1111/apm.12128.
9.
RaffelJGafsonAMalikO. Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler2015; In press.
